

# HEALTH AND WELLBEING BOARD 12 March 2015

ITEM 8

Report of the Director of Public Health

## **Pharmaceutical Needs Assessment update**

#### **SUMMARY**

- 1.1 The Health and Social Care Act 2012 transferred the responsibility for developing and updating Pharmaceutical Needs Assessments (PNAs) from Primary Care Trusts (PCTs) to Health and Wellbeing Boards (HWBs). The production of a PNA became the responsibility of Derby Health and Wellbeing Board from 1 April 2013.
- 1.2 In accordance with regulations, each Health and Well-being Board must:
  - Assess needs for pharmaceutical services in its area.
  - Publish a statement of its first assessment and of any revised assessment.
- 1.3 As approved at the Health and Wellbeing Board held on 11 September 2014, a draft PNA has been produced covering both Derby City and Derbyshire County (PNA and associated documents can be found here:

  <a href="http://www.derbyshire.gov.uk/pharmacyservices">http://www.derbyshire.gov.uk/pharmacyservices</a>). The draft document is required to be consulted on for a minimum of 60 days. The PNA is currently out for consultation (the link to the consultation has previously been circulated to Board members). The consultation closes on the 17 March 2015.
- 1.4 The draft document incorporates the minimum information requirements. It provides information on:
  - Overview of current provision.
  - Overview of findings of public consultation.
  - Profile of Derby.
  - Profile of Derbyshire and constituent localities.
- 1.5 The draft PNA concludes that the current provision of pharmaceutical services in the city and county meet the identified population needs.
- 1.6 The HWB is required to produce and publish the PNA by 1 April 2015.
- 1.7 The PNA will be reviewed in 2018 unless there are significant changes to local need or provision.

#### RECOMMENDATION

2.1 The Board is asked to note that a draft PNA document has been produced and is currently out for consultation.

2.2 Given the requirement of the HWB to publish its first PNA by 1 April, the Board is asked to give delegated responsibility to appropriate Board members (Director of Public Health; CCG representative; NHS England representative; and Chair) to approve a final version of the PNA for publication.

#### REASONS FOR RECOMMENDATION

3.1 To support the Health and Wellbeing Board in delivering its statutory responsibility to develop and publish a PNA.

#### SUPPORTING INFORMATION

- 4.1 The Health and Social Care Act 2012 amended the National Health Services Act 2006 and transferred the responsibility for developing and updating Pharmaceutical Needs Assessments (PNAs) from Primary Care Trusts (PCTs) to Health and Wellbeing Boards (HWBs). The production of a PNA became the responsibility of Derby Health and Wellbeing Board from 1 April 2013.
- 4.2 The pharmaceutical services to which each pharmaceutical needs assessment must relate are all the pharmaceutical services that may be provided under arrangements made by NHS England.
- 4.3 Responsibility for using PNAs as the basis for determining market entry to a pharmaceutical list transferred from PCTs to NHS England from 1 April 2013.
- 4.4 In accordance with regulations, each Health and Well-being Board must:
  - Assess needs for pharmaceutical services in its area
  - Publish a statement of its first assessment and of any revised assessment.
- 4.5 The development of a PNA is a separate duty to that of developing JSNA as PNAs will inform commissioning decisions by local authorities (public health services from community pharmacies) and by NHS England and clinical commissioning groups (CCGs).
- 4.6 Schedule 1 Regulation 4(1) of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 sets out the minimum information that must be contained in a PNA which in summary is:
  - Necessary services: current provision
  - Necessary services: gaps in provision
  - Other relevant services: current provision
  - Improvements and better access: gaps in provision
  - Other NHS services
  - How the assessment was carried out
  - Map of provision.
- 4.7 HWBs are required to produce their first assessment by 1 April 2015 and will be required to publish a revised assessment within three years of publication of their first assessment. HWBs will be required to publish a revised assessment as soon as is reasonably practical after identifying significant changes to the availability of pharmaceutical services since the publication of its PNA.

- 4.8 HWBs must consult the bodies set out in Regulation 8 at least once during the process of developing the PNA.
  - There is a minimum period of 60 days for consultation responses; and
  - Those being consulted can be directed to a website address containing the draft PNA but can, if they request, be sent an electronic or hard copy version.

### OTHER OPTIONS CONSIDERED

5.1 Consideration has been given to bringing the final version of the PNA to the May Health and Wellbeing Board for approval. This option would, however, mean that the Board would be unable to meet the deadline of publishing the PNA by 1 April.

This report has been approved by the following officers:

Legal officer Financial officer Human Resources officer	
Estates/Property officer Service Director(s) Other(s)	Derek Ward, Director of Public Health

For more information contact: Background papers:	Alison Wynn, 01332 643106, Alison.Wynn@derby.gov.uk PNA and associated documents – link:
List of appendices:	http://www.derbyshire.gov.uk/pharmacyservices Appendix 1 – Implications

## Appendix 1

#### **IMPLICATIONS**

## **Financial and Value for Money**

1.1 None.

## Legal

2.1 The Health and Social Care Act 2012 transferred responsibility for developing and updating of PNAs to Health and Wellbeing Boards (statutory sub-committee of the local authority). The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 set out the legislative basis for developing and updating PNAs.

#### Personnel

3.1 None.

IT

4.1 None.

## **Equalities Impact**

5.1 One of the key purposes of the PNA is to set out the local need for pharmaceutical services. This will include consideration of inequalities in health outcomes and access to pharmaceutical services.

## **Health and Safety**

6.1 None.

### **Environmental Sustainability**

7.1 None.

## **Property and Asset Management**

8.1 None.

#### **Risk Management**

9.1 The timeframe for publication in April 2015 is tight. To mitigate the risk of publishing within the required timeframes delegated responsibility for approving the final document has been sought.

### Corporate objectives and priorities for change

10.1	The production of a PNA will support the delivery of corporate objectives, particularly those relating to health and wellbeing.